
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a leader in the advanced wound care industry, with a diversified product portfolio that includes Apligraf, Dermagraft, and PuraPly. However, the company is facing reimbursement uncertainty due to changes made by CMS in 2026, resulting in a significant decline in revenue and profitability in the short term. Despite these challenges, Organogenesis has the potential to consolidate market share as smaller players exit, and its pipeline product ReNu could drive future revenue growth. We estimate the company's FY26 revenue to decline by ~29%, but see potential for normalized market conditions to drive higher numbers in the future. The company has a strong cash position and is well-positioned for future growth in the advanced wound care market.
Bears say
Organogenesis Holdings is facing many challenges that are negatively impacting its financial performance and stock outlook. These include a lower rev growth profile compared to its peers, disruptions in claims processing due to the new WISeR pilot program, uncertainties around CMS reimbursement policies, and new frictions in the market as providers navigate these changes. Additionally, the company has a negative free cash flow and a sizeable net loss projected for the next few years, leading to concerns about its financial stability. Collectively, these factors contribute to a negative outlook for Organogenesis Holdings' stock.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares